Consultant Rheumatologist

NHS Contact Details


Telephone: +44 (0)20 8385 3040


Ankylosing Spondylitis, early inflammatory arthritis, gout, hypermobility

  • Developing and testing new therapies to treat rheumatic diseases
  • Ankylosing Spondylitis
  • Gout
  • Inflammatory rheumatic diseases

Dr Mittal is a Consultant Rheumatologist and clinical lead for Ankylosing Spondylitis services at the Royal National Orthopaedic Hospital, Stanmore. She also holds appointments of Honorary Clinical Senior Lecturer, University College of London, and Honorary Visiting Scientist, Queen Mary University London. Dr Mittal conducts specialist clinics in Hypermobility and general clinic in Rheumatology at the RNOH. She is currently researching on developing a novel uricase-based therapy for gout and novel physical/rehabilitation therapies for Ankylosing Spondylitis.

Dr Mittal is experienced in managing the whole spectrum of common and uncommon rheumatologic disorders. Her special clinical interests include early inflammatory arthritis, early inflammatory low back pain, gout, hypermobility and complex systemic rheumatic diseases.

Dr Mittal’s specialist training in the UK includes North East Thames Rheumatology Rotation, Clinical Research Fellowship at Bangor, North Wales, and undertaking PhD at Bone and Joint Research Unit, London. Prior to coming to the UK in 2002, she worked as Senior Registrar in Rheumatology at a private tertiary centre in Mumbai, India.

  • Barts and the London Charity Clinical Training Fellowship
  • Ross Clinical Research fellowship, North Wales
  • John E Lawrence Fellowship, Massachusetts General Hospital, Boston

  • Pfizer Rare Disease Conference – Elevator Pitch Award
  • Queen Mary, Proof of Concept Award
  • Overseas Research Students Award Scheme Award, Queen Mary School of Medicine

  • Royal College of Physicians, London
  • British Society of Rheumatology

  • Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C, Foster J, Francis-West P, Köster M, Hauser H, Layward L, Vessillier S, Annenkov A, Al-Izki S, Pryce G, Bolton C, Baker D, Gould DJ, Chernajovsky Y. Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv.2014, 1:5-16.
  • Mullen, L, Adams, G, Vessillier, S, Rigby, A, Sclanders, M, Mittal, G, Colston, J, Fatah, R, Subang, M Francis-West, P, Köster, M, Hauser, H, Layward, L, Annenkov, A, Al-Izki, S, Pryce, G, Bolton, C, Baker, D, Gould, D and Chernajovsky, Y. Latent cytokines for targeted therapy of inflammatory disorders. Expert Opin Drug Deliv.2014, 1:101-110.
  • Lisa Mullen, Gill Adams, Rewas Fatah, David Gould, Anne Rigby, Michelle Sclanders, Apostolos Koutsokeras, Gayatri Mittal, Sandrine Vessillier and Yuti Chernajovsky. Development of latent cytokine fusion proteins. In fusion protein technologies for biopharmaceuticals: applications and challenges, Stefan R Schmidt (ed), March 2013.
  • Mittal G, Mason L, Isenberg D. Immunopathogenesis of systemic lupus erythematosus. Future Rheumatology 2007; 2:93-103.
  • Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumour necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006; 84:1463-72.
  • Mittal G, Maddison PJ, Williams W. Systemic sclerosis, morphea and breast cancer. Rheumatology 2006; 45:119-120
  • Mittal G, Maddison P. Drs. Mittal and Maddison reply: Altitude and Giant Cell Arteritis. J Rheumatol. 2005; 32:964.
  • G Mittal, N Hasso, P Maddison. Primary vasculitis at high altitude: Case report. J Rheumatol 2004;31:1450-1.
  • Mittal GA, Joshi VR, Deshpande A. Stromal cell-derived factor-1 alpha in rheumatoid arthritis. Rheumatology 2003; 42:915-6.
  • G Mittal, Z Udwadia, VR Joshi. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2003; 30: 1121-22.